Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Iovance reported Q1 2026 total revenue of ~$71 million, a 45% increase year-over-year, driven by record demand for Amtagvi and Proleukin. The company raised its full-year 2026 revenue guidance to $350 million-$370 million and announced positive initial data from its IOV-END-201 trial, showing a 40% confirmed objective response rate in metastatic serous endometrial cancer. With a cash position of ~$319 million, Iovance expects to fund operations well into 2028, though Chief Medical Officer Dr.
Key figures
- Revenue
- 71430000
- Guidance
- 2Q26 revenue $86M-$88M; FY26 revenue $350M-$370M
- Revenue Yoy
- 45%
- Gross margin
- 41%
- Cash position
- $319 million
- Amtagvi revenue
- $60 million
- Endometrial c ORR
- 40%
- Proleukin revenue
- $11 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.